Zhao Ziqi, Xu Kun, Hu Boqian, Jiang Yizhuo, Xu Xisheng, Liu Yuliang
School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Hebei Provincial Hospital of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
Front Immunol. 2025 Jan 16;15:1519498. doi: 10.3389/fimmu.2024.1519498. eCollection 2024.
Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs. This bibliometric analysis examines the 100 most-cited articles to elucidate trends and advancements in research concerning the gut microbiota's impact on ICI efficacy.
A systematic literature retrieval was conducted within the Web of Science Core Collection (WoSCC), focusing on the 100 most-cited articles. VOSviewer and CiteSpace were utilized for bibliometric analysis, examining collaborative patterns and keyword co-occurrences. The relationship between citing and cited entities was analyzed, and burst ranking identified research hotspots based on citation frequency.
The 100 most-cited publications encompassed a range of disciplines, with a predominance of oncological research. The United States and China were leading in publication volume, with France and Canada also contributing significantly. French institutions, particularly INSERM and Université Paris Cite, were prolific. Routy, Bertrand and Zitvogel, Laurence were prominent among high-impact authors. Dominant keywords included "gut microbiota," "immunotherapy," "efficacy," and "cancer." The article by Routy et al. (2018) was the most frequently cited.
This study highlights the significant role of the gut microbiota in ICI development and efficacy, emphasizing the necessity for international and interdisciplinary collaboration. The research is progressively focusing on managing immunotherapy side effects and optimizing treatment strategies. Challenges, including individual variability in gut microbiota composition, persist. Further research is imperative to exploit the potential of the gut microbiota in cancer therapy, advocating for personalized approaches and a more profound comprehension of the underlying mechanisms.
免疫检查点抑制剂（ICIs）通过调节针对肿瘤的免疫反应改变了肿瘤治疗。然而，其疗效存在患者间差异，并与免疫相关不良事件（irAEs）有关。人类肠道微生物群是一个复杂的微生物生态系统，越来越多地参与调节对ICIs的反应。这项文献计量分析研究了被引用次数最多的100篇文章，以阐明关于肠道微生物群对ICI疗效影响的研究趋势和进展。
在科学网核心合集（WoSCC）内进行系统的文献检索，重点关注被引用次数最多的100篇文章。使用VOSviewer和CiteSpace进行文献计量分析，研究合作模式和关键词共现情况。分析引用与被引用实体之间的关系，并通过爆发排名根据引用频率确定研究热点。
被引用次数最多的100篇出版物涵盖了一系列学科，其中肿瘤学研究占主导地位。美国和中国在出版物数量上领先，法国和加拿大也有显著贡献。法国机构，特别是法国国家健康与医学研究院（INSERM）和巴黎西岱大学，成果丰硕。鲁蒂（Routy）、贝特朗（Bertrand）和齐特沃格尔（Zitvogel）、劳伦斯（Laurence）是高影响力作者中的佼佼者。主要关键词包括“肠道微生物群”“免疫疗法”“疗效”和“癌症”。鲁蒂等人（2018年）的文章被引用频率最高。
本研究强调了肠道微生物群在ICI开发和疗效中的重要作用，强调了国际和跨学科合作的必要性。该研究正逐渐侧重于管理免疫治疗的副作用和优化治疗策略。包括肠道微生物群组成的个体差异在内的挑战依然存在。必须进一步开展研究，以挖掘肠道微生物群在癌症治疗中的潜力，倡导个性化方法并更深入地理解潜在机制。
